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Abstract
Background: Cyclooxygenase-2 (COX-2) is the inducible isoform of the cyclooxygenase enzyme family. COX-2 is
involved in tumor development and progression, and frequent overexpression of COX-2 in a variety of human
cancers has made COX-2 an important drug target for cancer treatment. Non-invasive imaging of COX-2 expression
in cancer would be useful for assessing COX-2-mediated effects on chemoprevention and radiosensitization using
COX-2 inhibitors as an emerging class of anti-cancer drugs, especially for colorectal cancer. Herein, we describe the
radiopharmacological analysis of [18F]Pyricoxib, a novel radiolabeled COX-2 inhibitor, for specific PET imaging of
COX-2 in colorectal cancer.
Methods: Uptake of [18F]Pyricoxib was assessed in human colorectal cancer cell lines HCA-7 (COX-2 positive) and
HCT-116 (COX-2 negative). Standard COX-2 inhibitors were used to test for specificity of [18F]Pyricoxib for COX-2
binding in vitro and in vivo. PET imaging, biodistribution, and radiometabolite analyses were included into
radiopharmacological evaluation of [18F]Pyricoxib.
Results: Radiotracer uptake in COX-2 positive HCA-7 cells was significantly higher than in COX-2 negative HCT-116
cells (P < 0.05). COX-2 inhibitors, celecoxib, rofecoxib, and SC58125, blocked uptake of [18F]Pyricoxib in HCA-7 cells
in a concentration-dependent manner. The radiotracer was slowly metabolized in mice, with approximately 60 % of
intact compound after 2 h post-injection. Selective COX-2-mediated tumor uptake of [18F]Pyricoxib in HCA-7
xenografts was confirmed in vivo. Celecoxib (100 mg/kg) selectively blocked tumor uptake by 16 % (PET image
analysis; P < 0.05) and by 51 % (biodistribution studies; P < 0.01).
Conclusions: The novel PET radiotracer [18F]Pyricoxib displays a promising radiopharmacological profile to study
COX-2 expression in cancer in vivo.
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Background
Cyclooxygenases (COXs) are responsible for the complex
conversion of arachidonic acid into prostaglandins, which
exert as autocrine or paracrine messengers a wide range of
physiological functions mediated through binding to pros-
taglandin E (EP) G-protein-coupled receptors (EP1-EP4)
[1]. The COX enzyme family consists of two distinct iso-
forms; COX-1, which is a constitutively expressed enzyme;
and COX-2, which is the inducible form of the enzyme.
COX-1 functions as a housekeeping enzyme and is
expressed in most tissues types. The enzyme is responsible
for maintaining homeostasis (gastric and renal integrity)
and normal production of eicosanes [1]. COX-2 is only
expressed in response to inflammatory stimuli and virtually
absent in most resting tissues [2]. COX-2 expression is
usually significantly upregulated under acute and chronic
inflammatory conditions [3], as well as in neurodegenera-
tive diseases like Parkinson’s and Alzheimer’s [4] and a var-
iety of cancers [5].
COX-2 has become an extensively studied drug target,
and numerous selective COX-2 inhibitors (coxibs) have
been developed [6]. Various selective COX-2 inhibitors
were in widespread clinical use from when they first
gained FDA approval in 2000. However, most coxibs were
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withdrawn from the market in 2005 following concerns
over their cardiac safety profiles [7]. Despite its evident
involvement in a variety of disease conditions, the mul-
tiple pathogenic and non-pathogenic roles of COX-2 in
human physiology have not been fully explored yet. A
recent shift in COX paradigm suggests that balance be-
tween COX-1 and COX-2 expression is of crucial im-
portance. Recent studies on biochemical mechanisms
that underline the cardiac toxicity of coxibs support
this theory [8, 9].
Elevated COX-2 expression was also demonstrated in
many human cancers such as colorectal, gastric, and breast
cancer [10–13]. Although several aspects of the molecular
mechanisms underlying COX-2 expression in cancer and
inflammatory lesions have been elucidated [14], there are
discrepancies between the potent anti-cancer effects of sev-
eral COX-2 inhibitors in pre-clinical studies and their fail-
ure in the majority of clinical trials [15]. The development
of techniques for non-invasive monitoring of COX-2 func-
tional expression would greatly facilitate efforts to under-
stand the COX-2 pharmacology in a living organism.
To date, an exact assessment of COX-2 expression can
only be achieved by laborious analyses ex vivo. Ex vivo
analysis of COX-2 is not particularly accurate since COX-
2 mRNA and protein are not stable outside the body and
degrade rapidly [16]. Nuclear molecular imaging tech-
niques such as positron emission tomography (PET) and
single-photon emission computed tomography (SPECT)
would provide unique opportunities to collect data on
COX-2 expression levels in vivo during disease develop-
ment, its progression, and the involvement of COX-2 in
various diseases. Over the past decade, more than two
dozen of PET and SPECT radiotracers for COX-2 imaging
have been developed. A comprehensive overview of the
advances in the field and the challenges surrounding the
identification of a suitable radiotracer for COX-2 imaging
has been the subject of several recent reviews [17–19].
However, despite the large number of structurally diverse
radiolabeled COX-2 inhibitors, most of them based on the
celecoxib backbone [20, 21], none was suitable for mo-
lecular imaging of COX-2 in pre-clinical models of can-
cer due to lack of sufficient uptake levels in vivo. A
recent attempt from our research team transforming a
successful in vitro fluorescence-labeled celecoxib de-
rivative into a 18F-labeled radiotracer also failed be-
cause no sufficient trapping in COX-2 expressing
tumors was detected [22]. Based on that, the goal of the
present study was to evaluate an alternative COX-2 ra-
diotracer based on a pyrimidine scaffold [23] for the
first time in vivo. We wanted to analyze if [18F]Pyri-
coxib, which radiosynthesis we had developed recently,
would be a better PET imaging probe for assessment of
functional expression of COX-2 in a pre-clinical human
colorectal cancer model in vitro and in vivo.
Methods
Radiochemistry
Radiosynthesis of [18F]Pyricoxib was performed as re-
cently described [20]. Details on the radiosynthesis and
the formulation of [18F]Pyricoxib for in vitro and in vivo
studies are described in detail in the Additional file 1.
Cell uptake studies
In vitro evaluation of [18F]Pyricoxib was performed with cell
lines HCA-7 (human colon adenocarcinoma; colony 29,
ECACC 2091238) and HCT-116 (human colorectal carcin-
oma; ATCC CCL-247). Cellular uptake experiments using
[18F]Pyricoxib (300 kBq/mL; specific activity >40 GBq/
μmol) were performed in triplicates in Krebs buffer at 37 °C
with 5-, 10-, 15-, 30-, 60-, 90-, and 120-min incubation time.
For blocking studies, cells were pre-incubated for 30 min
with 10 and 100 μM of Pyricoxib, celecoxib, rofecoxib, or
SC58125 prior to the addition of [18F]Pyricoxib.
Blocking experiments were performed at 60 min. Ra-
diotracer uptake was stopped by the addition of 1 mL of
ice-cold PBS. Then, cells were washed two times with
PBS and lysed in 0.4 mL of radioimmunoprecipitation
assay buffer (RIPA buffer). Radioactivity of cell lysates
was determined with a WIZARD2 Automatic gamma
counter (Perkin Elmer; Waltham, MA, USA). Total pro-
tein concentration in the samples was determined by the
bicinchoninic acid method (BCA; Pierce, Thermo Scien-
tific 23227) using bovine serum albumin (800, 600, 400,
300, 200, 100, 50 μg/mL, blank) as protein standard. Cell
uptake data are expressed as percent of measured radio-
activity per 1 mg protein (%radioactivity/mg protein).
Further information on cell culture protocols can be
found in the Additional file 1.
In vivo tumor model
All animal experiments were carried out in accordance
with the guidelines of the Canadian Council on Animal
Care (CCAC) and approved by the local animal care com-
mittee (Cross Cancer Institute, University of Alberta).
Positron emission tomography (PET) and biodistribu-
tion experiments were carried out in HCA-7 and HCT-
116 tumor-bearing NIH-III nude mice (Charles River La-
boratories, Quebec, Canada). Female NIH-III nude mice
were housed under standard conditions with free access
to standard food and tap water. HCA-7 and HCT-116
cells (5 × 106 cells in 100 μL of PBS) were injected into the
upper left flank of female NIH-III nude mice (20–
24 g). After 14 to 21 days post-inoculation, HCA-7
and HCT-116 tumors reached sizes of approximately
0.6–0.9 cm3 (0.78 ± 0.15 g, as determined during bio-
distribution experiments) which were suitable for all
in vivo experiments.
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Radiometabolite analysis
The radiotracer [18F]Pyricoxib (10 MBq) was injected intra-
venously into female NIH-III nude mice under isoflurane
anesthesia. Blood samples from the tail vein (20–40 μL)
were collected at 5, 30, 60, and 120 min p.i. Plasma was
separated by centrifugation (5 min, 13,000×g) followed by
plasma protein precipitation using ice-cold methanol (two
parts per one part plasma) and centrifugation (5 min,
13,000×g). Supernatants were analyzed by radio thin-layer
chromatography (radio-TLC). TLCs were developed in 1 %
MeOH/CH2Cl2 and analyzed using a BAS-5000 reader.
[18F]Pyricoxib had an Rf of 0.45 to 0.50 in this solvent
system.
Biodistribution studies in mice
NIH-III mice (body weight 21 ± 2 g) bearing subcutaneous
HCA-7 tumors were intravenously injected with 3–7 MBq
of [18F]Pyricoxib in 200 μL of solvent (10 % EtOH/H2O).
A second group of NIH-III mice (body weight 21 ± 2 g)
bearing HCA-7 tumors were treated with 2 mg of cele-
coxib administered via intraperitoneal injection in 100 %
DMSO 60 min prior to intravenous injection of [18F]Pyri-
coxib (3–7 MBq) in 200 μL of solvent (10 % EtOH/H2O).
Animals were sacrificed at 60 min p.i. The organs and tis-
sues of interest were rapidly excised, weighed, and the
radioactivity was determined using the automatic gamma
counter (see above). Radioactivity in the selected tissues
and organs was calculated as percent injected dose per
gram tissue (%ID/g). Data were analyzed as means ±
standard deviation (mean ± SD) for n = 4 animals.
Pre-clinical PET imaging
General anesthesia of HCA-7 tumor-bearing mice was in-
duced with inhalation of isoflurane in 40 % oxygen/60 %
nitrogen (gas flow = 1 mL/min), and mice were subse-
quently fixed in prone position. The body temperature was
kept constant at 37 °C for the entire experiment. For PET
experiments, 3–8 MBq of [18F]Pyricoxib in 150 μL of solu-
tion (formulation see Additional file 1) was administered
intravenously as a bolus injection into the tail vein. PET
data was collected dynamically over 60 min for up to 4 h
using an Inveon® PET/CT scanner (Siemens Preclinical So-
lutions, Knoxville, TN, USA). For the initial 4-h dynamic
PET experiments, 3.5 % HSA was added to the final injec-
tion solution, while all other experiments were done with-
out addition of carrier protein HSA. Mean standardized
uptake values [SUVmean = (activity/mL tissue)/(injected ac-
tivity/body weight), mL/g] were calculated for each region
of interest (ROI) with a threshold defined at 50 % of radio-
activity uptake. The time-activity curves (TACs) were gen-
erated from dynamic PET scans. All semi-quantified PET
data are presented as means ± SEM. In the blocking exper-
iments, COX-2 inhibitor celecoxib (2 mg per animal) in
100 μL DMSO was injected intraperitoneally 60 min prior
to radiotracer administration. Detailed information on
PET acquisition and data analysis can be found in the
Additional file 1.
Protein analysis
Standard Western blotting methods were used to deter-
mine COX-2 and COX-1 protein content. Detailed de-
scription can be found in the Additional file 1.
Immunohistochemistry for detection of COX-2 and CD68
Triplicates of HCA-7 and HCT116 tumors were excised
from euthanized mice, fixed in neutral buffered 10 %
formalin overnight and embedded in paraffin. The
sections of 4-μm thickness were dried in an oven at
60 °C for 1 h. The sections were rehydrated by pla-
cing the slides in three changes of xylene for 10 min
each, then graded ethanol from 100 to 50 %, followed
by water and Tris-buffered saline. Slides were micro-
waved in a pressure cooker for 6 min in citraconic
anhydride (0.05 % in water, pH 7.4) for antigen
retrieval.
Slides were blocked with 0.5 % fish gelatine in Tris-
buffered saline with 0.05 % Tween-20 (TBST) and incu-
bated with mouse monoclonal anti-CD68 antibody (clone
KPI, sc-20060, Santa Cruz Biotechnology, 1:300) or goat
polyclonal anti-COX-2 (clone M-19, sc-1747, Santa Cruz
Biotechnology, 1:3000) in a humidity chamber overnight
at 4 °C. After incubation in 3 % H2O2 in water for 15 min,
samples for detecting CD68 were incubated with DakoCy-
tomation Envision + anti-mouse HRP-labelled polymer
(DakoCytomation, Glostrup, Denmark) for 1 h, while sam-
ples for detecting COX-2 were treated with Goat Probe
for 15 min, followed by Goat-on-Rodent HRP-polymer
(Biocare Medical, Concord, USA) for another 15 min.
Slides were developed, using Dako Liquid DAB+ Substrate
Chromagen System plus 1 % copper sulfate and counter-
stained with hematoxylin. Slides were dehydrated by re-
versing rehydration procedure and cover slipped.
Statistical analysis
All in vitro data are expressed as means ± SEM, all in vivo
data as means ± SD. Graphs were constructed using Graph-
Pad Prism 4.0 (GraphPad Software). Where applicable, stat-
istical differences were tested by unpaired Student’s t test
and were considered significant for P < 0.05.
Results
Chemistry and radiochemistry
Synthesis of Pyricoxib-labeling precursor (N-(4-fluoroben-
zyl)-4-[4-(methylsulfonyl)-phenyl]-6-(trifluoro-methyl)pyri-
midin-2-amine) 1 and [18F]Pyricoxib have previously been
described by Tietz et al. [24, 25]. Pyricoxib was evaluated
for its COX-2 inhibitory potency and selectivity profile in
an in vitro inhibition assay. Pyricoxib displayed excellent
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COX-2 inhibitory potency (IC50 7 nM) which was higher
than that of celecoxib (IC50 40 nM). Pyricoxib did not
show COX-1 inhibition in the concentration range
tested [24]. Radiosynthesis of [18F]Pyricoxib based on the
reaction of bis-methylsulfone precursor 1 with 4-[18F]fluor-
obenzylamine ([18F]FBA) was accomplished within
95 min including HPLC purification in radiochemical
yields of 27 ± 11 % (Fig. 1a).
Cell uptake studies
Human colorectal cancer cell lines HCA-7 (COX-2 posi-
tive) and HCT-116 (COX-2 negative) were used to study
the uptake of [18F]Pyricoxib in vitro. High baseline ex-
pression of COX-2 in HCA-7 cells is well documented,
as well as the lack of COX-2 expression in HCT-116
cells [26]. This was further confirmed by Western blot
analysis (Fig. 1b). Cellular uptake of [18F]Pyricoxib was
Fig. 1 a Radiosynthesis of [18F]Pyricoxib utilizing building block 4-[18F]fluoro-benzylamine ([18F]FBA). b Western blot analysis of COX-1 and COX-2
in cell lysates of HCA-7 and HCT-116 cell lines. c Uptake of [18F]Pyricoxib into HCA-7 and HCT-116 cells over 90 min. Data are normalized as %radioactivity
per mg protein and shown as mean ± SEM from n= 3 experiments. d Blocking of [18F]Pyricoxib uptake (60-min incubation time) into HCA-7 cells using
high concentrations (0.1 mM) of different selective COX-2 inhibitors. Data are normalized as % radioactivity per mg protein and shown as mean ± SEM from
nine data points out of three experiments. e Concentration dependent inhibition of [18F]Pyricoxib uptake (60-min incubation time) into HCA-7 cells. Data
are normalized as % maximum uptake of [18F]Pyricoxib and analyzed as mean ± SEM from nine data points out of three experiments.
*P< 0.05; ***P< 0.001
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significantly higher in HCA-7 cells compared to HCT-
116 cells (Fig. 1c). After 90 min, uptake in HCA-7 cells
reached 598 ± 93 % %radioactivity/mg of protein (n = 3),
while uptake in HCT-116 cells was significantly lower
reaching 317 ± 36 % %radioactivity/mg protein (n = 3) at
the same time point.
COX-2 specificity of radiotracer uptake in HCA-7 cells
was tested with cellular uptake inhibition studies using vari-
ous selective COX-2 inhibitors. Cells were pre-incubated
with 10 and 100 μM of various COX-2 inhibitors (cele-
coxib, rofecoxib, SC58125, and Pyricoxib) for 30 min prior
to the addition of radiotracer [18F]Pyricoxib. Figure 1d
shows inhibitory effects of selective COX-2 inhibitors at
high concentration (100 μM) on the uptake of [18F]Pyri-
coxib normalized as %radioactivity/mg protein. The results
in Fig. 1e demonstrate that radiotracer uptake in HCA-7
cells could be reduced in a concentration-dependent man-
ner, although to a different extent.
Inhibition of radiotracer uptake was strongest with cel-
ecoxib which resulted in an inhibition of 35 % at 10 μM
and 65 % at 100 μM, followed by Pyricoxib > rofecoxib >
SC58125, respectively. Novel COX-2 inhibitor Pyricoxib
inhibited radiotracer uptake by 35 and 50 % at inhibitor
concentrations of 10 and 100 μM, respectively.
Radiometabolite analysis
Radiometabolite analysis of blood samples revealed that ra-
diotracer [18F]Pyricoxib was only slowly metabolized in
NIH-III mice. The percentage of intact [18F]Pyricoxib de-
creased from 98 % at 5 min p.i. to 60 % at 2 h p.i. The con-
tent of detectable radioactivity in plasma fraction increased
from 30 % after 5 min to 50 % after 2 h p.i., while radio-
activity amount in the blood cell fraction decreased over
time. The levels of radioactivity bound to plasma proteins
did not change over 2 h and remained low in the range of 2
to 7 %. The following blood compartment distribution of
radioactivity was determined—5 min: 68 % blood cells, 2 %
plasma proteins, and 30 % plasma supernatant; 30 min:
54 % blood cells, 4 % plasma proteins, and 42 % plasma
supernatant; and 60 min: 43 % blood cells, 7 % plasma pro-
teins, and 50 % plasma supernatant, respectively.
Dynamic PET imaging of HCA-7 tumor-bearing mice
Figure 2 shows a representative PET/CT image of a HCA-
7 tumor-bearing mouse after 2 h p.i. of [18F]Pyricoxib. An-
alyzed time-activity curves (TACs) describe continuous in-
crease of radioactivity accumulation in the tumor over 4 h
reaching a standardized uptake value (SUV4h) of 1.19 ±
0.13 (n = 7). Radioactivity in the muscle as reference tissue
peaked at 60 min p.i. (SUV60min 0.61 ± 0.14) followed by a
slow washout over time (SUV4h 0.53 ± 0.11; n = 7) leading
to a tumor-to-muscle ratio of 2.25 after 4 h p.i.
COX-2 specificity of radiotracer uptake in HCA-7 tumors
was studied in a second series of experiments. Figure 3 de-
picts transaxial, coronal, and sagittal PET images of radio-
activity distribution after 60 min p.i. in HCA-7 tumor-
bearing mice without celecoxib (top) and in the presence of
2 mg of celecoxib given by i.p. injection 60 min prior to ra-
diotracer administration.
Tumors in the pre-treated animals clearly showed re-
duced radioactivity accumulation. Figure 4 summarizes
quantification of blocking experiments. Each blocking
experiment was performed on two consecutive days
using the same animal first studied with a baseline scan
(control) followed by a PET scan after pre-treatment the
animal with celecoxib (2 mg).
Uptake of radiotracer [18F]Pyricoxib in HCA-7 tumors
after 60 min p.i. in control animals resulted in a mean
SUV of 0.75 ± 0.12 (n = 6), which was significantly higher
than radioactivity uptake in pre-treated animals (SUV =
0.57 ± 0.20, n = 6; *P = 0.05).
SUV of 0.57 ± 0.20 in HCA-7 tumors of pre-treated ani-
mals was in the same range as the SUV measured in the
muscle as reference tissue (0.50 ± 0.11; n = 6) at the same
time point. Pre-treatment with celecoxib did not impair
Fig. 2 Left: PET/CT image (coronal slice) 2 h after injection of [18F]Pyricoxib into a HCA-7 tumor-bearing NIH-III mouse. 3.5 % HSA was added as
carrier protein to the final injection solution. Right: Time-activity curves for tumor uptake of [18F]Pyricoxib and its clearance from muscle tissue
over 4 h post injection. Data are shown as mean ± SD from seven dynamic PET experiments
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Fig. 3 Top: transaxial, coronal, and sagittal PET images at 60 min p.i. of [18F]Pyricoxib into HCA-7 tumor-bearing NIH-III mouse (control); bottom:
transaxial, coronal, and sagittal PET images at 60 min p.i. of [18F]Pyricoxib into HCA-7 tumor-bearing NIH-III mouse (pre-treated with 2 mg of celecoxib
60 min prior to radiotracer administration; no HSA added)
Fig. 4 Left: analysis of PET imaging-derived standardized uptake values (SUV) for HCA-7 tumor uptake and muscle clearance over 60 min p.i. of
[18F]Pyricoxib in the presence and absence of 100 mg/kg (2 mg per mouse) celecoxib. No HSA was added. Right: statistical analysis of the blocking effect
with 2 mg celecoxib on the SUV at 60 min p.i. All data are shown as mean ± SD from six experiments. *P< 0.05
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muscle uptake which is further indicative that ob-
served inhibitory effects in tumor tissue were COX-2
mediated.
Biodistribution studies in HCA-7 tumor-bearing mice
Results obtained from PET imaging experiments were
confirmed by complementary biodistribution studies.
Results of biodistribution experiments are summa-
rized in Table 1. Pre-treatment with 2 mg of cele-
coxib (100 mg/kg) led to a significant reduction of
radiotracer uptake into HCA-7 tumors. Control ani-
mals showed a tumor uptake of 2.12 ± 0.53 %ID/g
after 60 min p.i., whereas celecoxib-treated animals
displayed a significantly reduced tumor uptake of
1.04 ± 0.30 %ID/g (**P < 0.01).
The presence of celecoxib also reduced uptake in fatty
tissue, led to an increase in blood retention (**P < 0.01) as
well as an increase in uptake in a number of other tissues
and organs (the heart, lung, liver, kidney, stomach, pan-
creas, and brain). Increase in lung uptake confirmed the
observed “first pass pulmonary retention” as a known
phenomenon for selected secondary amines such as local
anesthetics, e.g., lidocaine [27].
PET imaging and biodistribution in HCT-116 tumor-
bearing mice
In addition to the COX-2 expressing tumor cell line HCA-
7, tumors were also generated from non-COX-2 express-
ing HCT-116 cells (see Fig. 1b). Injection of [18F]Pyricoxib
into HCT-116 tumor-bearing mice resulted in comparable
levels of radioactivity uptake as observed in HCA-7 tu-
mors (Fig. 5b, c): SUV2h 0.93 ± 0.06 (HCT-116; n = 3) ver-
sus 1.09 ± 0.13 (HCA-7; n = 3). Biodistribution analysis
confirmed that finding (Fig. 5d). Analysis of COX-2 pro-
tein content in HCT-116 tumors confirmed COX-2 ex-
pression, which was absent in HCT-116 cells (Fig. 5a).
Induced expression of COX-2 upon injection of HCT-
116 cells into mice explains the observed uptake of ra-
diotracer [18F]Pyricoxib in HCT-116 tumors. This find-
ing excludes HCT-116 tumors as a COX-2-negative
tumor model in vivo.
Immunohistochemical detection of COX-2 and CD68
Immunohistochemical staining was used as an additional
method to detect COX-2 protein in HCA-7 and HCT116
tumor tissue. In addition, tissues were also analyzed for
CD68, which is a surface marker for various cells with
macrophage/monocyte origin in association with inflam-
mation processes [28]. As images in Fig. 6 show, a strong
and clear staining for COX-2 was observed in HCA-7
tumor tissues.
In contrast, HCT-116 tumor tissue was mainly COX-2
negative, except of several inclusion cells, revealing very
strong COX-2 staining intensity leading to some COX-2
expression in HCT-116 tissue samples. These inclusion
cells morphologically may not represent tumor cells, but
this has not been confirmed in full detail.
In addition, only very few CD68 positive cells were de-
tected in HCA-7 tumors, while no staining for CD68
was detected in HCT-116 tumors.
Discussion
Over the last two decades, numerous PET and SPECT
radiotracers have been developed for COX-2 imaging.
Several radiotracers have been subject of pre-clinical
evaluation for molecular imaging of COX-2 expression
in inflammation and cancer [17–19]. However, most of
the reported radiotracers failed to visualize COX-2
in vivo due to multiple challenges including low meta-
bolic stability, insufficient inhibitory potency and specifi-
city for COX-2, and high non-specific binding to other
targets. These challenges are especially pronounced for
experiments aimed at molecular imaging of COX-2 in
various pre-clinical cancer models. As a result, none of
the reported radiotracers could demonstrate specific
interaction with COX-2 in vivo. Therefore, to date, no
successful imaging strategy for COX-2 in cancer has
been described. The reasons for the failure of successful
Table 1 Biodistribution of [18F]Pyricoxib in control (left) and
treated (right) HCA-7 tumor-bearing NIH-III mice (n = 4)
[18F]Pyricoxib [18F]Pyricoxib + 2 mg celecoxib
Organ
Blood 0.65 ± 0.12 0.98 ± 0.09
Heart 2.52 ± 0.54 5.70 ± 1.58
Lung 3.75 ± 0.66 52.26 ± 43.08
Liver 17.13 ± 1.22 25.47 ± 2.44
Kidneys 4.38 ± 1.01 8.40 ± 0.77
Spleen 1.24 ± 0.33 2.72 ± 0.65
Stomach 1.08 ± 0.29 3.96 ± 2.73
Duodenum 4.59 ± 0.73 5.18 ± 1.31
Intestine (small) 8.08 ± 2.33 6.66 ± 1.95
Intestine (large) 4.21 ± 1.74 3.48 ± 0.80
Pancreas 3.92 ± 1.39 7.22 ± 2.87
Bone 0.67 ± 0.19 1.05 ± 0.16
Ovaries 8.22 ± 1.27 4.97 ± 2.84
Brain 1.74 ± 0.51 3.79 ± 0.56
Fat 12.67 ± 5.45 5.80 ± 3.84
Muscle 1.42 ± 0.54 1.59 ± 0.64
HCA-7 tumor 2.12 ± 0.53 1.04 ± 0.30**
Tumor/muscle 1.81 ± 1.04 0.70 ± 0.19
Tumor/blood 3.39 ± 0.55 1.09 ± 0.41
Data are displayed as means ± SD %ID/g after 60 min p.i
**P < 0.05
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Fig. 5 a Western blot analysis of COX-2 in HCA-7 and HCT-116 cell lysates as well as tumor samples generated from these cells. b Transaxial, coronal,
and sagittal PET images at 120 min post injection of [18F]Pyricoxib into HCT-116 tumor-bearing NIH-III mouse. c Time-activity curves for HCT-116 tumor
uptake of [18F]Pyricoxib in comparison to its uptake into HCA-7 tumors over 2 h post injection. Data are shown as mean ± SD from three dynamic PET
experiments. d HCA-7 and HCT-116 tumor uptake determined from ex vivo biodistribution 2 h after injection of [18F]Pyricoxib. Data are shown as
mean ± SD from three experiments each
Fig. 6 Immunohistochemical staining with COX-2 (top) and CD-68 (bottom) antibody in tumor tissue slices from NIH-III mice bearing HCA-7 (left)
and HCT-116 (right) tumors
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molecular imaging of COX-2 in vivo can be attributed to
a major extent to unfavorable radiopharmacological pro-
file of the radiotracers tested, but the selection and
utilization of suitable pre-clinical models to study COX-
2 radiotracers seems to be equally challenging.
In this study, we evaluated novel COX-2 radiotracer
[18F]Pyricoxib in HCA-7 mouse xenografts as a pre-
clinical model of colorectal cancer. Radiotracer [18F]Pyri-
coxib contains a 6-membered trifluoromethyl pyrimidine
core structure and a methylsulfone COX-2 pharmaco-
phore, which is different to most of the recently developed
and tested COX-2 inhibitors like celecoxib and valdecoxib
containing 5-membered heterocyclic core structure and a
sulphonamide COX-2 pharmacophore [17–22].
Radiotracer [18F]Pyricoxib was prepared in good radio-
chemical yields of about 27 % using 4-[18F]fluorobenzy-
lamine as readily available 18F building block [25] within
a substitution reaction using 2-(methyl-sulfonyl)-4-(4-
(methyl-sulfonyl)phenyl)-6-(trifluoro-methyl)-pyrimidine
1 as the radiolabeling precursor.
The radiotracer was shown to possess reasonable meta-
bolic stability in vivo, reaching 60 % of intact [18F]Pyricoxib
after 2 h p.i. in mice. Moreover, radiotracer [18F]Pyricoxib
exhibited high inhibitory potency and selectivity for COX-2
(IC50 7 nM) versus COX-1 (IC50 >100 μM).
IC50 values of various selective COX-2 inhibitors to-
wards COX-2 inhibition such as celecoxib (40 nM, deter-
mined in the same assay as Pyricoxib [24]), SC58125
(10 nM [29]), and rofecoxib (18–26 nM [30]) confirm that
Pyricoxib displays COX-2 inhibitory potency comparable
or higher to that of selected COX-2 inhibitors used as
blocking agents in this study. Based on its pharmacological
properties, [18F]Pyricoxib meets two basic requirements
for a successful PET imaging agents—high metabolic sta-
bility and high inhibitory potency and selectivity for the
target in the nanomolar range. Data on muscle clearance
profile of [18F]Pyricoxib as reference for non-target tissue
clearance suggest that an optimal imaging time window
for [18F]Pyricoxib would be at 120 min p.i. or longer rather
than 60 min p.i.
However, COX-2 is located inside the membrane of the
endoplasmic reticulum. Consequently, radiotracers need
to cross various biological membranes to reach the COX-
2 binding site. For this purpose, a favorable lipophilicity
profile is required, and the lipophilicity of [18F]Pyricoxib
was determined to be a log P of 3.37. This value is in the
range to allow for passive diffusion, and it is also in the
same range as reported lipophilicity values of other radi-
olabeled COX-2 inhibitors [17–19]. Cellular uptake stud-
ies of [18F]Pyricoxib in human colorectal cell lines HCA-7
and HCT-116 demonstrated significantly higher radio-
tracer uptake and retention in COX-2-positive HCA-7
cells. However, overall uptake of the radiotracer was also
sufficiently high in COX-2-negative HCT-116 cells. This
finding is indicative of a favorable passive diffusion profile
of the radiotracer in combination with COX-2-mediated
uptake and retention mechanisms in the case of COX-2-
expressing HCA-7 cells. In COX-2-negative HCT-116
cells, several COX-2 independent uptake and retention
mechanisms are likely to be responsible for the observed
radiotracer uptake.
Immunohistochemical analysis confirmed a high expres-
sion of COX-2 in HCA-7 tumors with lower but noticeable
COX-2 expression in HCT-116 tumors. This is consistent
with the Western blot analysis of both HCA-7 and HCT-
116 tumor samples (Fig. 5). Both tumors showed negative
staining for CD68 as marker for tumor-associated macro-
phages [31]. This finding indicates that observed positive
staining for COX-2 in HCT-116 tumors is not related to
the infiltration of COX-2-expressing macrophages as an in-
flammatory response to tumor cell inoculation and tumor
growth.
Reduction of radiotracer uptake in HCA-7 cells in re-
sponse to pre-treatment with various COX-2 inhibitors
in a concentration-dependent manner indicated that cel-
lular uptake and retention of [18F]Pyricoxib is largely re-
lated to specific binding to COX-2.
However, blocking efficacy varied among the applied
COX-2 inhibitors and was most evident with celecoxib.
No complete blockage of radiotracer uptake could be
achieved, and the remaining radioactivity levels of >35 %
even at high inhibitor concentrations of 100 μM is indi-
cative of some non-specific intracellular binding of the
radiotracer.
Interactions of radiotracer [18F]Pyricoxib with COX-2
and non-COX targets would explain the observed broad
variety in blocking efficacy using different COX-2 inhibi-
tors, assuming that every used compound possesses a
distinct affinity and selectivity profile for both COX and
non-COX targets.
However, given the data determined during the
present study, it is not possible to speculate about the
nature of potential non-COX targets, although some
secondary targets have been identified in the literature.
Most of the research in this area focused on celecoxib
[32–34]. COX-2 inhibitors like celecoxib do not interact
with COX-2 alone; they can also interact with a variety
of other molecular targets.
Celecoxib was shown to directly target Ca2+ ATPase,
protein-dependent kinase 1 (PDK-1), cycline-dependent ki-
nases (CDKs) in concert with various cyclins, and carbonic
anhydrases (CA) [32]. Direct inhibition of these proteins by
celecoxib allows the drug to exert anti-carcinogenic proper-
ties in a COX-2 independent manner. Although coxibs are
selective for COX-2 over COX-1, the assumption that these
molecules are truly “selective drugs” is faulty. The thera-
peutic efficacy of drugs like celecoxib and rofecoxib can
not only be attributed to the inhibition of arachidonic acid
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metabolism through inhibition of COX-2 enzyme exclu-
sively. Data on the non-COX affinity profile for Pyricoxib is
not available, but since celecoxib, rofecoxib, and Pyricoxib
share a number of key COX-2 pharmacophores, the possi-
bility that they share a number of non-COX molecular tar-
gets must be considered. However, at this point, potential
non-COX interactions of radiotracer [18F]Pyricoxib were
not further analyzed during this study.
Pre-clinical PET imaging experiments provided further
evidence of COX-2-mediated uptake of [18F]Pyricoxib in
COX-2-expressing HCA-7 tumors.
Consistent with cellular uptake results in COX-2-
expressing HCA-7 cells, this radiotracer showed steady
uptake in HCA-7 tumors with no wash-out of radioactiv-
ity over time. COX-2-mediated retention of [18F]Pyricoxib
in HCA-7 tumors was confirmed by in vivo blocking
experiments.
Pre-dosing of HCA-7 tumor-bearing mice with 2 mg of
celecoxib per mouse resulted in a 16 % decrease of radio-
activity uptake in the tumor at 60 min p.i., while the
remaining ~80 % may be related to non-specific and non-
COX-2-mediated interactions. The biodistribution data in
control and treated animals revealed a 50 % blocking ef-
fect which confirmed selective COX-2-mediated uptake of
[18F]Pyricoxib in HCA-7 tumors.
However, overall uptake in the muscle was also high,
and only very slow clearance of radioactivity from muscle
tissue was observed. Under normal physiological condi-
tions, muscle tissue does not express COX-2 [2].
Therefore, the observed high uptake and retention of
radioactivity in muscle tissue may also be related to non-
COX-2-mediated interactions of [18F]Pyricoxib. The lit-
erature provides some examples of possible mechanisms.
A recent study showed that celecoxib is able to inhibit G-
protein-coupled drug efflux pumps and thereby enhance
the intracellular retention of drugs [32].
Drug efflux pumps serve as one possible example of
targets for non-COX-2 specific interactions of molecules
designed on the typical coxib structural scaffold.
A number of these non-COX targets have been identified
for celecoxib as typical example of the coxib drug family
[32–34]. A COX-2 radiotracer recently developed by Uddin
et al. serves as a good comparison to [18F]Pyricoxib in
terms of non-COX-2 specific interaction [21]. The re-
searchers developed an 18F-labeled celecoxib derivative and
evaluated the radiotracer in a COX-2 inflammation model
and a COX-2 tumor model. They showed a reduction of
radiotracer uptake in a carrageenan-induced inflammation
model in response to pre-treatment with celecoxib. How-
ever, the observed overall uptake level of the radiotracer
(SUV 0.2) might be too low to be COX-2 specific, espe-
cially considering the high non-specific uptake of celecoxib
in a variety of organs and tissues. Celecoxib contains the
typical sulfonamide COX-2 pharmacophore. Various
sulfonamides including celecoxib are also known to have a
low nanomolar affinity for the members of the carbonic
anhydrase (CA) enzyme family [33].
A reduction in uptake of a radiolabeled celecoxib de-
rivative in response to treatment with celecoxib might
therefore be representative of an interaction with CA ra-
ther than with COX-2.
In contrast, [18F]Pyricoxib contains a methylsulfone
COX-2 pharmacophore which does not interact with
CAs, but [18F]Pyricoxib displayed COX-2 specific inter-
actions in vitro and in vivo. However, the observed mul-
tiple non-COX-2-mediated interactions of radiotracer
[18F]Pyricoxib still represent a major challenge.
However, it must be concluded that non-specific interac-
tions of COX-2 inhibitors like [18F]Pyricoxib are inevitable
due to their rather high lipophilic nature, which is neces-
sary to cross biological membranes to reach the binding
site of COX-2 located inside of the endoplasmic reticulum.
Conclusions
We developed a novel PET imaging assay for non-invasive
detection of functional expression of COX-2 in cancer
using radiolabeled COX-2 inhibitor [18F]Pyricoxib. Despite
the inherent major challenges associated with the develop-
ment of COX-2 selective radiotracers for PET imaging of
COX-2 in vivo, we believe that radiotracer [18F]Pyricoxib
based on a pyrimidine scaffold does show the best and
most selective tumor uptake profile in COX-2-expressing
tumors as analyzed in a pre-clinical in vivo model so far.
Our own previous and unsuccessful attempts of developing
a celecoxib-based 18F-radiotracer [22] for imaging COX-2
in vivo would support that alternative structure selection.
The novel imaging assay represents an important basis
for translation into a “first-in-man” clinical study to assess
COX-2 in vivo. Non-invasive imaging of COX-2 expression
with [18F]Pyricoxib in cancer would be useful for assessing
COX-2-mediated effects on chemoprevention and radio-
sensitization using COX-2 inhibitors as an emerging class
of anti-cancer drugs, especially for colorectal cancer.
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